Bio-Path Holdings, Inc. (BPTH) vs Lyra Therapeutics, Inc. (LYRA)

Bio-Path Holdings, Inc. and Lyra Therapeutics, Inc. are both Biotechnology companies. Bio-Path Holdings, Inc. is the larger, with a market value of $1.1M against $870.0K — 1.2× the size. Bio-Path Holdings, Inc. has the higher net margin (0.00% vs −7,266.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Bio-Path Holdings, Inc. leads on 9 and Lyra Therapeutics, Inc. on 3.

Valuation

Metric BPTH LYRA Biotechnology median
P/E n/m n/m 7.88
P/S n/m 0.78 11.47
P/B n/m n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.00 0.51 0.74
EV/Sales n/m (39.15) 10.73
Earnings yield 0.00% (9,575.00%) (28.84%)
Free cash flow yield 0.00% (9,304.25%) (23.03%)

Profitability

Metric BPTH LYRA Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (7,794.47%) 0.00%
Net margin 0.00% (7,266.08%) 0.00%
Free cash flow margin 0.00% (7,261.06%) 0.00%
Return on equity 157.01% (6,594.98%) (57.72%)
Return on assets (605.50%) (56.45%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BPTH LYRA Biotechnology median
Revenue growth (TTM) — (74.05%) 5.64%
EPS growth (last fiscal year) 87.75% 73.96% —
Revenue growth, 5-year CAGR — (20.38%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BPTH LYRA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.07 1.71 4.73
Net debt to EBITDA 0.10 0.52 0.96

Dividend

Metric BPTH LYRA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BPTH LYRA Biotechnology median
Market cap 1.07m 870.00k 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack